Clinical Trials · us
Limited Options After CNS Lymphoma Relapse, Dual-Pathway Blockade Shows Early Efficacy Signal
Curis has updated early trial results for emavusertib combined with ibrutinib: responses were more concentrated among patients with no prior BTK inhibitor use, while some tumor shrinkage was also seen in previously treated patients; however, the small patient numbers and differing cohort designs are not yet sufficient to confirm the magnitude of efficacy.
Once primary central nervous system lymphoma relapses or becomes resistant to treatment, the available options quickly narrow; the clinical situation is particularly challenging when the disease has also progressed after treatment with a BTK inhibitor. The latest data released by Curis show that combining emavusertib with ibrutinib to simultaneously block two signaling pathways in tumor cells may produce renewed objective responses in some patients, but this remains a preliminary signal from a small, early-stage trial.
As of July 1, 2026, 6 of 7 patients who had never received a BTK inhibitor achieved an objective response, for an objective response rate of 86% among all enrolled patients; all 5 patients who had completed at least one treatment cycle and were evaluable for efficacy responded. The 100% figure excludes two patients who had not yet completed approximately one month of treatment and therefore better reflects the early evaluable cases, but it cannot replace the result for the entire enrolled population.
Among 39 patients who had previously received a BTK inhibitor, 10 achieved an objective response, corresponding to 26% of the overall group; among the 30 patients who had completed at least one treatment cycle, the rate was 33%. The significance of this cohort is that the patients had already failed treatment with the same class of drugs, but the single-arm, nonrandomized design cannot rule out the effects of patient selection, the timing of subsequent assessments, and other clinical differences, nor can it demonstrate that adding emavusertib is superior to existing management.
Emavusertib is an oral small-molecule inhibitor of IRAK4 and FLT3, while ibrutinib inhibits BTK. The biological rationale proposed by Curis is to suppress TLR and B-cell receptor signaling separately, reducing from both directions the survival signals that converge on NF-κB. This mechanism provides a rationale for the combination therapy, but it must still be confirmed by larger-scale clinical data with a control group; long-term benefit cannot be inferred from response rates alone.
Trial registration data show that NCT03328078 is a multicenter, open-label Phase 1/2 study expected to enroll 152 participants. Part B nonrandomly evaluates the combination of emavusertib and ibrutinib in patients whose disease progressed after BTK inhibitor treatment; Part C randomly assigns patients who have not received a BTK inhibitor to emavusertib, ibrutinib, or the two-drug combination. This means that the current figures for the two patient groups come from different study frameworks and should not be directly compared or interpreted as an efficacy difference caused by prior treatment.
The registration data list the estimated primary completion date as August 2026, with the overall study expected to be completed in October of the same year. The key questions ahead include not only how many patients experience tumor shrinkage, but also how long responses are maintained, disease control and survival outcomes, and more complete safety data. The company’s announcement did not provide sufficient detail to comprehensively assess these issues; until the randomized cohort matures and undergoes full analysis, this combination should still be regarded as an experimental treatment supported by a clinical hypothesis but with evidence that has not yet been established.